-
The World's First! Bristol-Myers Squibb's Red Blood Cell Maturation Agent Liblose® Launched in Chin...
On June 14, Bristol-Myers Squibb announced that the world's first and currently only red blood cell maturation agent, Liblose®
2022-06-14 17:42 -
AstraZeneca/Mersk & Co.'s MEK Inhibitor Filed for Listing in China
On June 13, the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China...
2022-06-14 09:58 -
Eli Lilly's GIPR/GLP-1R Dual Agonist Tirzepatide Patent Layout
On May 13, 2022, the U.S. Food and Drug Administration approved Eli Lilly and Company's Mounjaro™ (tirzepatide) injection
2022-06-13 16:51 -
Tonghua Dongbao's 'Liraglutide Injection' Declared for Listing
On June 9, the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that Tonghua Dong...
2022-06-10 15:15 -
Tirzepatide Enters the Field of Weight Loss and Will Achieve a 'Small Goal' of Over 10 Billion US Do...
Eli Lilly announced the clinical trial results at the 82nd annual meeting of the American Diabetes Association (ADA) in New Orleans on Saturday (June ...
2022-06-10 13:36 -
Pfizer to Increase Production Capacity of Coronavirus Oral Drugs, Invest 120 Million US Dollars
Pfizer disclosed in its first quarterly report in 2022 that the sales revenue of Paxlovid, an oral drug for the new crown, was US$1.5 billion.
2022-06-09 14:05 -
The World's First CD20/CD3 Double Antibody Was Approved for Marketing
On June 8, Roche announced that the European Commission has granted a conditional marketing authorization for the CD20xCD3 T cell-binding bispecific a...
2022-06-09 13:58 -
FDA Approves Blockbuster Anti-inflammatory Drug for Infants with Eczema
Today, Regeneron and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of pediatri...
2022-06-08 13:40 -
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
Pfizer disclosed in its first quarterly report in 2022 that the sales revenue of Paxlovid, an oral drug for the new crown, was US$1.5 billion.
2022-06-08 13:36 -
Regeneron Buys Cancer Drug from Sanofi
Recently, Regeneron agreed to purchase the immuno-oncology drug Libtayo (simipritimab) from its partner Sanofi in a transaction amounting to US$1.1 bi...
2022-06-07 10:34
Hot News
- After Two Price Hikes in One W... Mar 10, 2026
- Urea Prices Surge as India Fac... Mar 16, 2026
- Middle East Conflict Pushes Up... Mar 18, 2026
- Sudden Turmoil in Middle East ... Mar 05, 2026
- Hormuz in Crisis: Freight Rate... Mar 04, 2026
Related Products
Related Producers
